

Berch
10/821695

Page 1

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 16:14:56 ON 01 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

2 sided

~~Handwritten signature~~

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 FEB 2006 HIGHEST RN 875516-18-0

DICTIONARY FILE UPDATES: 28 FEB 2006 HIGHEST RN 875516-18-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> e amorphous cefdinir/cn 5

E1 1 AMORPHOPHALLUS RIVIERI, EXT./CN

E2 1 AMORPHOUS ACONITINE/CN

E3 0 --> AMORPHOUS CEF DINIR/CN

E4 2 AMORPHOUS SILICA/CN

E5 1 AMORPHOUS SILICA FUME/CN

=> fil medline;e amorphous cefdinir/ct 5

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.88

1.09

FILE 'MEDLINE' ENTERED AT 16:16:12 ON 01 MAR 2006

FILE LAST UPDATED: 28 FEB 2006 (20060228/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).
See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

E#	FREQUENCY	AT	TERM
E1	1		AMORPHOPHALLUS: ME, METABOLISM/CT
E2	1		AMORPHOPHALLUS: PH, PHYSIOLOGY/CT
E3	0	-->	AMORPHOUS CEFDINIR/CT
E4	0	2	AMOSITE/CT
E5	0	2	AMOSITE ASBESTOS/CT

=> fil biosis

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.39	1.48

FILE 'BIOSIS' ENTERED AT 16:16:17 ON 01 MAR 2006
Copyright (c) 2006 The Thomson Corporation

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 22 February 2006 (20060222/ED)

=> 'e amorphous cefdinir/ct 5

E#	FREQUENCY	AT	TERM
E1	1		AMORPHOUS CARBONATED CALCIUM PHOSPHATE/CT
E2	1		AMORPHOUS CDTR-PI/CT
E3	0	-->	AMORPHOUS CEFDINIR/CT
E4	2		AMORPHOUS CEFDITOREN PIVOXIL/CT
E5	1		AMORPHOUS CEFDITOREN PIVOXIL SUBSTANCE/CT

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.87	2.35

FILE 'CAPLUS' ENTERED AT 16:16:29 ON 01 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Mar 2006 VOL 144 ISS 10
FILE LAST UPDATED: 28 Feb 2006 (20060228/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> e amorphous cefdinir/ct 5

E#	FREQUENCY	AT	TERM
E1	0	2	AMORPHOUS ALUMINUM ALLOYS/CT
E2	0	2	AMORPHOUS ALUMINUM-BASED ALLOYS/CT
E3	0	-->	AMORPHOUS CEFDINIR/CT
E4	0	2	AMORPHOUS COBALT ALLOYS/CT
E5	0	2	AMORPHOUS COBALT-BASED ALLOYS/CT

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.46	2.81

FILE 'REGISTRY' ENTERED AT 16:16:36 ON 01 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 FEB 2006 HIGHEST RN 875516-18-0
DICTIONARY FILE UPDATES: 28 FEB 2006 HIGHEST RN 875516-18-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> e cefdinir/cn 5

```
E1      1      CEFCLIDINE/CN
E2      1      CEFDALOXIME/CN
E3      1 -->  CEFDINIR/CN
E4      1      CEFDINIR DICYCLOHEXYLAMINE SALT/CN
E5      1      CEFDINIR MONOHYDRATE/CN
```

=> e

```
E6      1      CEFDINIR NITRATE/CN
E7      1      CEFDINIR PHOSPHATE/CN
E8      1      CEFDITERON/CN
E9      1      CEFDITOREN/CN
E10     1      CEFDITOREN ACID/CN
E11     1      CEFDITOREN NITRATE/CN
E12     1      CEFDITOREN PIVALOYLOXYMETHYL ESTER/CN
E13     1      CEFDITOREN PIVOXIL/CN
E14     1      CEFDITOREN PIVOXYL/CN
E15     1      CEFDITOREN POTASSIUM/CN
E16     1      CEFDITOREN POTASSIUM DIHYDRATE/CN
E17     1      CEFDITOREN POTASSIUM MONOHYDRATE/CN
```

=> s e3-e7

```
1 CEFDINIR/CN
1 "CEFDINIR DICYCLOHEXYLAMINE SALT"/CN
1 "CEFDINIR MONOHYDRATE"/CN
1 "CEFDINIR NITRATE"/CN
1 "CEFDINIR PHOSPHATE"/CN
L1      5 (CEFDINIR/CN OR "CEFDINIR DICYCLOHEXYLAMINE SALT"/CN OR "CEFDINI
R MONOHYDRATE"/CN OR "CEFDINIR NITRATE"/CN OR "CEFDINIR PHOSPHAT
E"/CN)
```

=> fil medl,biosis,embase,caplus;s ll or ll<chem>

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	24.24	27.05

FILE 'MEDLINE' ENTERED AT 16:17:14 ON 01 MAR 2006

FILE 'BIOSIS' ENTERED AT 16:17:14 ON 01 MAR 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 16:17:14 ON 01 MAR 2006

Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 16:17:14 ON 01 MAR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

SmartSELECT INITIATED

New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	3.15	30.20

FILE 'REGISTRY' ENTERED AT 16:17:14 ON 01 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

SET SMARTSELECT ON
SET COMMAND COMPLETED

SEL L1 1- CHEM
L2 SEL L1 1- CHEM : 15 TERMS

SET SMARTSELECT OFF
SET COMMAND COMPLETED

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	11.29	41.49

FILE 'MEDLINE' ENTERED AT 16:17:15 ON 01 MAR 2006

FILE 'BIOSIS' ENTERED AT 16:17:15 ON 01 MAR 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 16:17:15 ON 01 MAR 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 16:17:15 ON 01 MAR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

S L1 OR L2

L8 275 FILE MEDLINE
L9 389 FILE BIOSIS
L10 921 FILE EMBASE
L11 503 FILE CAPLUS

TOTAL FOR ALL FILES
L12 2088 L1 OR L7

=> s l12(1)amorphous
L13 0 FILE MEDLINE
L14 0 FILE BIOSIS
L15 0 FILE EMBASE
L16 4 FILE CAPLUS

TOTAL FOR ALL FILES

L17 4 L12(L) AMORPHOUS

=> d 1-4 ibib abs hitstr

L17 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:122978 CAPLUS
 TITLE: Preparation of stable **amorphous cefdinir**
 INVENTOR(S): Sever, Nancy E.; Law, Devalina
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 18 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006029674	A1	20060209	US 2005-103183	20050411
PRIORITY APPLN. INFO.:			US 2004-560957P	P 20040409

AB The present invention relates to preps. of stable **amorphous cefdinir** (7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4-carboxylic acid, syn isomer), methods for its preparation, and pharmaceutical comps. comprising the same. **Amorphous cefdinir** was isolated by evaporating a methanolic solution of **cefdinir hydrate**. The **amorphous** material was phys. stable.


IT 213978-34-8, **Cefdinir monohydrate**

RL: RCT (Reactant); RACT (Reactant or reagent)
 (stable **amorphous cefdinir**)

RN 213978-34-8 CAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[[[(2Z)-(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-
 , monohydrate, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




IT 91832-40-5, **Cefdinir**

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stable amorphous cefdinir)

RN 91832-40-5 CAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[[(2Z)-(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-
, (6R,7R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:100935 CAPLUS

DOCUMENT NUMBER: 144:170819

TITLE: Cefdinir polymorphic forms, and imidazole salt

INVENTOR(S): Jaweed Mukarram, Siddiqui Mohammed; Khan, Rashid Abdul
Rehman; Mane, Avinash Seshrao

PATENT ASSIGNEE(S): Wockhardt Limited, India

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006010978	A1	20060202	WO 2004-IB2171	20040630
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:

WO 2004-IB2171

20040630

GI




AB A new crystalline **Cefdinir** imidazole salt (I) and polymorphic forms C, D and an **amorphous** form of **Cefdinir** were disclosed.

IT 91832-40-5P, **Cefdinir**
 RL: PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of the **Cefdinir** imidazole salt and **amorphous** and polymorphic crystalline forms C and D of **Cefdinir**, a β -lactam antibiotic)

RN 91832-40-5 CAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[[[(2Z) - (2-amino-4-thiazolyl) (hydroxyimino)acetyl]amino] -3-ethenyl-8-oxo-
 , (6R,7R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:1154562 CAPLUS
 DOCUMENT NUMBER: 143:427351
 TITLE: Preparation of stable **amorphous** **cefdinir**
 INVENTOR(S): Server, Nancy E.; Law, Devalina
 PATENT ASSIGNEE(S): Abbott Laboratories, USA
 SOURCE: PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005100368	A2	20051027	WO 2005-US12439	20050411
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2004-821695 A 20040409

AB The present invention relates to stable **amorphous cefdinir** (syn isomer), methods for its preparation, and pharmaceutical compns. comprising the stable **amorphous** form. **Amorphous cefdinir** was characterized with Eudragit EPO.


IT 213978-34-8P, **Cefdinir monohydrate**

RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of stable **amorphous cefdinir**)

RN 213978-34-8 CAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z) - (2-amino-4-thiazolyl) (hydroxyimino) acetyl] amino] -3-ethenyl-8-oxo-, monohydrate, (6R,7R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




● H₂O

IT 91832-40-5P, **Cefdinir**

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of stable **amorphous cefdinir**)


RN 91832-40-5 CAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[[[(2Z)-(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-
 , (6R,7R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



L17 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:453223. CAPLUS
 DOCUMENT NUMBER: 141:6966
 TITLE: Process for preparing cefdinir and its
 amorphous hydrate
 INVENTOR(S): Deshpande, Pandurang Balwant; Khadangale, Bhausaheb
 Pandharinath; Ramasubbu, Chandrasekaran
 PATENT ASSIGNEE(S): Orchid Chemicals & Pharmaceuticals Ltd., India
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046154	A1	20040603	WO 2003-IB5032	20031110
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			IN 2002-MA848	A 20021115
			IN 2003-MA152	A 20030226
OTHER SOURCE(S):			CASREACT 141:6966; MARPAT 141:6966	
GI				



AB The present invention discloses a process for preparing cefdinir [I; R1 = H; R2 = CO₂H (II)] and its monohydrate via condensing 7-amino-3-cephem-4-carboxylic acid with III (X = ester, thioester, halo, etc.) in the presence of a tertiary amine and an organic solvent, followed by treatment with a base to produce I [R1 = C(Ph)₃; R2 = carboxylate ion (IV)], and hydrolyzing IV, using an acid in the presence of a solvent, to produce II. Thus, reaction between III (X = OH) and 2-mercapto-5-phenyl-1,3,4-oxadiazole yielded 2-mercapto-5-phenyl-1,3,4-oxadiazolyl-(Z)-(2-aminothiazol-4-yl)-2-(trityloxyimino) acetate, which, on condensation with 7-amino-3-vinyl-3-cephem-4-carboxylic acid and subsequent hydrolysis, afforded II.


IT 91832-40-5P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cefdinir and its amorphous hydrate)

RN 91832-40-5 CAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[[(2Z)-(2-amino-4-thiazolyl) (hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-
, (6R,7R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




IT 213978-34-8P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of cefdinir and its amorphous hydrate)

RN 213978-34-8 CAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[[(2Z)-(2-amino-4-thiazolyl) (hydroxyimino)acetyl]amino]-3-ethenyl-8-oxo-
, monohydrate, (6R,7R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● H2O

=> fil wpids;s ll or cefdinir?
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
70.69	112.18

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
-3.00	-3.00

CA SUBSCRIBER PRICE

FILE 'WPIDS' ENTERED AT 16:18:16 ON 01 MAR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE LAST UPDATED: 27 FEB 2006 <20060227/UP>
MOST RECENT DERWENT UPDATE: 200614 <200614/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
GUIDES, PLEASE VISIT:
<http://scientific.thomson.com/support/products/dwpi/>

>>> FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
FIRST VIEW - FILE WPIFV.
FOR FURTHER DETAILS:
<http://scientific.thomson.com/support/products/dwpifv/>

>>> THE CPI AND EPI MANUAL CODES WILL BE REVISED FROM UPDATE 200601.

PLEASE CHECK:

<http://scientific.thomson.com/support/patents/dwpieref/reftools/classification>

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE

http://www.stn-international.de/stndatabases/details/ipc_reform.html and

<http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf> <<<

1 CEFDINIR/CN
0 "CEFDINIR DICYCLOHEXYLAMINE SALT"/CN
0 "CEFDINIR MONOHYDRATE"/CN
0 "CEFDINIR NITRATE"/CN
0 "CEFDINIR PHOSPHATE"/CN
68 CEFDINIR?
L18 69 L1 OR CEFDINIR?

=> s l18 and amorphous
59099 AMORPHOUS

L19 4 L18 AND AMORPHOUS

=> d 1-4

L19 ANSWER 1 OF 4 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2006-136793 [14] WPIDS

DNC C2006-047045

TI New imidazole salt of syn-7-(2-(2-amino-4-thiazolyl)-2-hydroxyimino-acetamido)-3-vinyl-3-cephem-4-carboxylic acid (**Cefdinir**), crystalline form C and D and **amorphous** form of **Cefdinir** useful for treating bacterial infections.

DC B02

IN JAWEED MUKARRAM, S M; KHAN, R A R; MANE, A S

PA (MUKA-I) JAWEED MUKARRAM S M; (KHAN-I) KHAN R A R; (MANE-I) MANE A S; (WOCK-N) WOCKHARDT LTD

CYC 108

PI WO 2006010978 A1 20060202 (200614)* EN 33 C07D501-22

RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE
LS LU MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE
DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG
KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ
OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG
US UZ VC VN YU ZA ZM ZW

ADT WO 2006010978 A1 WO 2004-IB2171 20040630

PRAI WO 2004-IB2171 20040630

IC ICM C07D501-22

ICS C07D501-04

L19 ANSWER 2 OF 4 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2005-778983 [79] WPIDS

DNC C2005-238762

TI New stable **amorphous cefdinir** used to treat bacterial infections.

DC A11 A14 A96 B03

IN LAW, D; SERVER, N E

PA (ABBO) ABBOTT LAB

CYC 110

PI WO 2005100368 A2 20051027 (200579)* EN 27 C07D501-00

RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IS IT
KE LS LT LU MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG

ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE
DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG
KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO
NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ
UA UG US UZ VC VN YU ZA ZM ZW
ADT WO 2005100368 A2 WO 2005-US12439 20050411
PRAI US 2004-821695 20040409
IC ICM C07D501-00
L19 ANSWER 3 OF 4 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2004-449732 [42] WPIDS
DNC C2004-168548
TI Preparation of **cefdinir**, useful as an antibiotic, comprises
reaction of 7-amino-3-cephem-4-carboxylic acid with 5-amino-thiazine
derivative, tertiary amine and an organic solvent, followed by treatment
with a base and hydrolysis by an acid.
DC B02
IN DESHPANDE, P B; KHADANGALE, B P; RAMASUBBU, C
PA (ORCH-N) ORCHID CHEM & PHARM LTD
CYC 106
PI WO 2004046154 A1 20040603 (200442)* EN 26 C07D501-06
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS
LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE
DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG
PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ
VC VN YU ZA ZM ZW
AU 2003276525 A1 20040615 (200470) C07D501-06
ADT WO 2004046154 A1 WO 2003-IB5032 20031110; AU 2003276525 A1 AU 2003-276525
20031110
FDT AU 2003276525 A1 Based on WO 2004046154
PRAI IN 2003-CH152 20030226; IN 2002-CH848 20021115
IC ICM C07D501-06
ICS C07D501-22
L19 ANSWER 4 OF 4 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
AN 2002-586515 [63] WPIDS
CR 2001-343157 [36]
DNC C2002-166020
TI Manufacture of 3-cephem derivative crystal as pharmaceutical intermediates
e.g., cefixime, involves crystallizing **amorphous** powder or oily
substance of 3-cephem derivative using poor solvent containing carbon
dioxide.
DC B02
PA (SAKB) OTSUKA KAGAKU YAKUHI KK
CYC 1
PI JP 2002145885 A 20020522 (200263)* 8 C07D501-12
ADT JP 2002145885 A JP 2000-290561 20000925
PRAI JP 2000-267059 20000904; JP 1999-279080 19990930
IC ICM C07D501-12
ICS C07D501-20; C07D501-24; C07D501-59

=> dis his

(FILE 'HOME' ENTERED AT 16:14:35 ON 01 MAR 2006)

FILE 'REGISTRY' ENTERED AT 16:14:56 ON 01 MAR 2006.

E AMORPHOUS CEFDINIR/CN 5

FILE 'MEDLINE' ENTERED AT 16:16:12 ON 01 MAR 2006
E AMORPHOUS CEFDINIR/CT 5

FILE 'BIOSIS' ENTERED AT 16:16:17 ON 01 MAR 2006
E AMORPHOUS CEFDINIR/CT 5

FILE 'CAPLUS' ENTERED AT 16:16:29 ON 01 MAR 2006
E AMORPHOUS CEFDINIR/CT 5

FILE 'REGISTRY' ENTERED AT 16:16:36 ON 01 MAR 2006
E CEFDINIR/CN 5

L1 5 S E3-E7

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 16:17:14 ON 01 MAR 2006

FILE 'REGISTRY' ENTERED AT 16:17:14 ON 01 MAR 2006
SET SMARTSELECT ON
L2 SEL L1 1- CHEM : 15 TERMS
SET SMARTSELECT OFF

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 16:17:15 ON 01 MAR 2006

L3 275 FILE MEDLINE
L4 389 FILE BIOSIS
L5 921 FILE EMBASE
L6 503 FILE CAPLUS

TOTAL FOR ALL FILES

L7 2088 S L2
L8 275 FILE MEDLINE
L9 389 FILE BIOSIS
L10 921 FILE EMBASE
L11 503 FILE CAPLUS

TOTAL FOR ALL FILES

L12 2088 S L1 OR L7
L13 0 FILE MEDLINE
L14 0 FILE BIOSIS
L15 0 FILE EMBASE
L16 4 FILE CAPLUS

TOTAL FOR ALL FILES

L17 4 S L12(L) AMORPHOUS

FILE 'WPIDS' ENTERED AT 16:18:16 ON 01 MAR 2006

L18 69 S L1 OR CEFDINIR?
L19 4 S L18 AND AMORPHOUS

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
19.88	132.06

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-3.00

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 16:18:51 ON 01 MAR 2006